Ironwood Pharma (IRWD) Misses Q2 EPS by 12c; Reiterates Outlook

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.21, $0.12 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $97.23 million versus the consensus estimate of $103.55 million.

GUIDANCE:

Ironwood Pharma reiterates FY2022 revenue of $420-$430 million, versus the consensus of $428.80 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lucid reports Q2 output, names new CFO and five other leaders
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform